I will not tell you from where I get this info.
But in soon, this month we will hear from Board of Director result of Study of Cabozantinib (XL184) in Adults With Advanced Malignancies. Emerging data may support enrollment in an open-label, non-randomized expansion cohort (NRE) for prostate and ovarian cancers.
What do you think about the result? Dont forget insider just bought EXEL someday ago